Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study

Background. The treatment options for patients with multiple myeloma who refractory to previous bortezomib and lenalidomide therapy are limited. Pomalidomide is ап immunomodulatory agent that was registered for the treatment of patients with double refractory multiple myeloma.Aim. To evaluate effica...

Full description

Bibliographic Details
Main Authors: V. G. Potapenko, E. V. Baumert, A. A. Bobrova, R. V. Vashchenkov, N. V. Dorofeeva, K. D. Kaplanov, E. V. Karyagina, A. N. Levanov, A. S. Luchinin, S. I. Moiseev, A. V. Novitskii, A. S. Nizamutdinova, О. V. Pirogova, S. A. Povzun, М. V. Platonov, V. V. Porunova, D. А. Ptashnikov, V. V. Ryabchikova, S. Ya. Simeniv, I. А. Skorokhod, Е. А. Ukrainchenko, D. А. Chaginskaya, T. V. Shelekhova, M. N. Shirokova, A. A. Shutylev, N. V. Medvedeva
Format: Article
Language:Russian
Published: ABV-press 2022-07-01
Series:Онкогематология
Subjects:
multiple myeloma
pomalidomide
double refractory
triplet
lenalidomide
bortezomib
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/558

Internet

https://oncohematology.abvpress.ru/ongm/article/view/558

Similar Items